Evidence map›Paper›PMID 32559853›Full record

ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2020

DKK2 blockage-mediated immunotherapy enhances anti-angiogenic therapy of Kras mutated colorectal cancer.

Jiajia Hu, Zhengting Wang, Zhengxi Chen, Ao Li, Jing Sun, Minhua Zheng, Jibo Wu, Tianli Shen, Ju Qiao, Lin Li and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Jiajia HuDepartment of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Department of Pharmacology and Vascular Biology and Therapeutic Program, Yale School of Medicine, New Haven, CT, United States.
Zhengting WangDepartment of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhengxi ChenDepartment of Pharmacology and Vascular Biology and Therapeutic Program, Yale School of Medicine, New Haven, CT, United States; Department of Orthodontics, Shanghai Ninth People׳s Hospital, School of Stomatology, Shanghai Key Laboratory of Stomatology, Shanghai Jiao Tong University, Shanghai, China.
Ao LiDepartment of Pharmacology and Vascular Biology and Therapeutic Program, Yale School of Medicine, New Haven, CT, United States.
Jing SunDepartment of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Minhua ZhengDepartment of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jibo WuDepartment of Pharmacology and Vascular Biology and Therapeutic Program, Yale School of Medicine, New Haven, CT, United States; Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
Tianli ShenDepartment of Pharmacology and Vascular Biology and Therapeutic Program, Yale School of Medicine, New Haven, CT, United States; Department of General Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
Ju QiaoDepartment of Mechanical and Industrial Engineering, Northeastern University, Boston, MA, United States.
Lin LiInstitute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
Biao LiDepartment of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Dianqing WuDepartment of Pharmacology and Vascular Biology and Therapeutic Program, Yale School of Medicine, New Haven, CT, United States. Electronic address: dianqing.wu@yale.edu.
Qian XiaoDepartment of Pharmacology and Vascular Biology and Therapeutic Program, Yale School of Medicine, New Haven, CT, United States. Electronic address: qian.xiao@yale.edu.
Shanghai Jiao Tong University · CNYale University · USNortheastern University · USShanghai Institutes for Biological Sciences · CN

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
DKK2 regulates NK activation and tumor immunityR01CA214703 · NCI · YALE UNIVERSITY · PI WU, DIANQING · 2018 to 2022
$2.5M
Mechanisms for Wnt SignalingR01GM112182 · NIGMS · YALE UNIVERSITY · PI HA, YA, WU, DIANQING · 2014 to 2018
$1.5M
NCATS NIH HHS UL1 TR001863NCI NIH HHS R01 CA214703NIGMS NIH HHS R01 GM112182
6 · The paper itself

Abstract

There are limited options for targeted therapies for colorectal cancer (CRC). Anti-EGFR therapy is limited to CRC without KRAS mutations. Even worse, most of CRC are refractory to currently immune checkpoint blockade. DKK2, which is upregulated in CRC, was recently found to suppress host immune responses, and its blockage effectively impeded tumor progression in benign genetic CRC models in our previous study. Here, our recent study demonstrated that in human CRC tumor samples expressing high levels of DKK2, DKK2 blockade caused stronger activation of tumor infiltrating CD8

Indexed as

AdultAgedAged, 80 and overAnimalsAntibodiesCD8-Positive T-LymphocytesCell Line, TumorCell SurvivalColorectal NeoplasmsDrug SynergismHumansImmunotherapyIntercellular Signaling Peptides and ProteinsMiceMiddle AgedMutationAntibodiesDKK2 protein, humanIntercellular Signaling Peptides and ProteinsKRAS protein, humanProto-Oncogene Proteins p21(ras)Receptors, Vascular Endothelial Growth FactorAnti-VEGFRAPCDKK2Immune activationKRASTherapeutic approachesTumor microenvironment

Identifiers

PMID32559853
PMCPMC7523634
OpenAlexW3027192973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.